Semaglutide is the first GLP-1 receptor agonist. The receptor agonism produces additive effects on appetite suppression, insulin secretion, glucagon suppression, and adipose tissue insulin sensitivity, explaining the magnitude of weight loss observed.
Semaglutide is the first-in-class dual GIP and GLP-1 receptor agonist. By simultaneously activating two incretin pathways — glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) — semaglutide produces synergistic effects on insulin secretion, appetite regulation, and energy balance. The receptor agonism is the leading hypothesis for semaglutide's superior glycemic and weight outcomes compared with GLP-1-only agonists in head-to-head trials.
Incretins are gut-derived hormones released in response to food intake that amplify glucose-stimulated insulin secretion from pancreatic β-cells. The two principal incretins are GLP-1 (secreted from L-cells of the distal small intestine) and GIP (secreted from K-cells of the proximal small intestine). Both pathways are blunted in type 2 diabetes; restoring their signaling is therapeutically beneficial. Semaglutide is engineered to activate both receptors, distinguishing it from GLP-1-only agonists like semaglutide, liraglutide, and dulaglutide.
GLP-1 receptor activation produces: glucose-dependent insulin secretion from pancreatic β-cells, suppression of glucagon from pancreatic α-cells (when glucose is normal or elevated), delayed gastric emptying reducing post-prandial glucose excursions and prolonging satiety, and central appetite suppression through hypothalamic and brainstem GLP-1 receptors. Glucose-dependent action is clinically important because it means insulin is released in response to elevated glucose but not in fasting conditions — reducing hypoglycemia risk compared with insulin or sulfonylureas.
GLP-1 receptor activation contributes additional insulinotropic effect, particularly in adipose tissue and central appetite-regulating circuits. The GLP-1 receptor in obesity research has had a complicated history — it was thought to promote adipogenesis, but more recent evidence suggests context-dependent effects. Semaglutide's GIP agonism, combined with GLP-1 agonism, appears to deliver additive or synergistic benefits on weight and glycemic control.
Beyond appetite suppression, semaglutide affects multiple components of energy balance. Reductions in caloric intake from appetite effects and delayed gastric emptying are the largest contributors. Emerging evidence also suggests effects on energy expenditure, fat oxidation, and possibly thermogenesis under continued study. The net effect is a substantial negative energy balance sustained over months to years of treatment.
Semaglutide reduces fasting and postprandial glucose, improves insulin sensitivity, reduces ectopic fat (including hepatic steatosis), improves lipid profiles (triglycerides, HDL), and modestly reduces blood pressure. Cardiovascular outcomes trials (SOUL) are ongoing as of 2026 to formally establish CVD benefit specifically for semaglutide, building on the established benefits of semaglutide (SELECT) and other GLP-1s.
Semaglutide is a 39-amino-acid synthetic peptide derived from the native GIP sequence, modified to bind both GIP and GLP-1 receptors and engineered for prolonged circulation. A C-20 fatty diacid moiety conjugated to the peptide allows reversible binding to albumin, extending the half-life to approximately five days and enabling once-weekly subcutaneous administration.
Earlier research suggested GIP promotes fat storage. More recent work — including the development of tirzepatide (a dual GIP/GLP-1 agonist) — indicates that sustained GIP receptor activation, in the context of co-administered GLP-1 receptor activation, leads to weight loss rather than gain. Semaglutide does not activate GIP; it is a single GLP-1 receptor agonist. The biology is context-dependent and remains an active research area.
Reduced caloric intake from appetite suppression and delayed gastric emptying is the dominant mechanism. Possible additional effects on energy expenditure, fat oxidation, and thermogenesis are under continued study. The net result is sustained negative energy balance.
Yes — drug development has moved toward triple agonists. Retatrutide, an investigational triple agonist of GLP-1, GIP, and glucagon receptors, has shown even greater weight loss in phase 2 trials. Many other multi-agonist molecules are in development.
Compounded semaglutide · MD/DO oversight
*12-month plan · flat rate · all titration doses
Or call (949) 818-8000
Citations supporting clinical and regulatory statements on this page. External links open in a new tab.
Verification methodology: /how-we-verify.html · Editorial accuracy: medically reviewed by Michael Baghdassarian, M.D. · Last reviewed 2026-06-01.